EGFR and breast carcinoma: Treatment with THZ531 reduced the EGFR protein levels and sensitized HGSOC cells and PDOs to treatment with Lapatinib, a chemical inhibitor of the EGFR kinase activity currently in use for HER2-amplified breast cancer [48].